Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Male Breast Cancer|Progesterone Receptor-negative Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer
Interventions: DRUG: eribulin mesylate|DRUG: carboplatin|PROCEDURE: biopsy
Sponsor: Northwestern University
Collaborators: Eisai Inc.